Filtered By:
Specialty: International Medicine & Public Health
Nutrition: Vitamins

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 45 results found since Jan 2013.

Study On Drug Utilization And Assessment Of Stroke Risk Using Chads2 And Cha2ds2-Vasc Scoring In Elderly Patients With Non-Valvular Atrial Fibrillation
Stroke Risk Stratification in AF patients of can be done using CHADS2 (Congestive heart failure, Hypertension, Age ≥75, DM, prior Stroke/TIA [2 points] ); or CHA2DS2VASc2 (Congestive heart failure/left ventricular ejection fraction ≤35%, Hypertension, Age ≥75 [2 points], DM, prior Stroke/TIA/thromboembolism [2 points], Vascular disease, Age 65–74, Sex- female). Treatment options for Prevention of stroke includes Anti-coagulants (Vitamin K Antagonist-Warfarin, Acenocoumarol; and Newer Oral Anticoagulant- Dabigatran) and anti-platelets (Aspirin and Clopidogrel).
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: T. Raj, S. Bonthu, S.R. Mallayasamy Source Type: research

PM198 Antithrombotic Treatment in Relation to Age and Stroke Risk in Patients With Newly Diagnosed Atrial Fibrillation (Gloria-AF Phase II)
Vitamin K antagonists (VKAs) or the non-VKA oral anticoagulants (NOACs) are recommended for prevention of stroke in patients with atrial fibrillation (AF) and additional stroke risk factors. Phase II of the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) started after approval of dabigatran etexilate, the first NOAC available for stroke prevention in patients with AF.
Source: CVD Prevention and Control - May 31, 2016 Category: Global & Universal Authors: J. Halperin, M. Huisman, H.-C. Diener, S. Dubner, C. Ma, K. Rothman, J. Healey, K. Zint, C. Teutsch, G. Lip Tags: Poster Abstract Source Type: research

Risks of heart attack, stroke may outweigh benefits of calcium supplement
(Norwegian University of Science and Technology) Taking calcium and vitamin D can help prevent broken bones in older women. However, this benefit may be cancelled out by an increased risk of heart attack and stroke.
Source: EurekAlert! - Medicine and Health - May 12, 2016 Category: Global & Universal Source Type: news

How safe and effective are new drugs for stroke prevention?
(Mayo Clinic) For decades, warfarin was the only oral blood thinner available to reduce the risk of stroke for patients with atrial fibrillation. Warfarin use is cumbersome, because it requires ongoing blood test to monitor the effect and has numerous drug and food interaction. Now a number of non-vitamin K antagonist oral anticoagulant drugs are available for patients with atrial fibrillation and claim to revolutionize the care for patients with atrial fibrillation.
Source: EurekAlert! - Medicine and Health - October 3, 2016 Category: Global & Universal Source Type: news

Antithrombotic Treatments in Patients with Acute Ischemic Stroke and Non-Valvular Atrial Fibrillation Before Introduction of Non-Vitamin K Antagonist Oral Anticoagulants Into Practice in Korea
This multicenter observational study aimed to describe patterns of long-term antithrombotic use in acute ischemic stroke (AIS) patients with non-valvular atrial fibrillation (NVAF) in Korea and their impacts on clinical events before introduction of non-vitamin K antagonist oral anticoagulants (NOAC) into practice in 2015.
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: H Bae, J Heo, K Jung, Y Lee, K Hong, W Seo, J Koo, J Cha, MJ Lee, B Seo, Y Kim, S Kang, J Seok, J Lee, C Chung Source Type: research

Cost-Effectiveness of Apixaban In Prevention of Stroke And Systemic Embolism In The Czech Republic
Apixaban is an oral anticoagulant, direct factor Xa inhibitor. The aim of the analysis was to compare costs and effectiveness of apixaban in the first line prevention of stroke and systemic embolism in vitamin K antagonist (VKA) suitable patients with atrial fibrillation. The analysis was conducted from the perspective of the public healthcare payer in the Czech Republic.
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: M Kolek, T Spousta, M Karbusicka, P Vothova, P Mazan, J Duba Source Type: research

Vitamin D and estradiol help guard against heart disease, stroke, and diabetes
(The North American Menopause Society (NAMS)) Vitamin D and estrogen have already shown well-documented results in improving bone health in women. A new study from China suggests that this same combination could help prevent metabolic syndrome, a constellation of conditions that increases the risk of heart disease, stroke, and diabetes in postmenopausal women. Results are published online today in Menopause, the journal of The North American Menopause Society (NAMS).
Source: EurekAlert! - Medicine and Health - June 12, 2019 Category: International Medicine & Public Health Source Type: news

Apixaban In Patients With Atrial Fibrillation: Patient Characteristics Of The Latin America Cohort From A Multinational Clinical Trial
Patients with Atrial fibrillation (AF), have a five-fold increase in the risk of stroke. Treatment for AF include stroke prevention therapy. Vitamin K antagonists (VKAs) have shown to prevent stroke in AF patients. Apixaban, a novel oral direct factor Xa inhibitor was studied in AF patients whom VKA therapy was unsuitable. Apixaban demonstrated clinical benefit in stroke or systemic embolism reduction without impacting the risk of major bleeding or intracranial hemorrhage. Patient characteristics of the Latin America (LA) cohort and overall population are presented.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: A Avezum, MC Bahit, JA Hermosillo, FL Zanetti, P Perafan, A Juarez-Garcia, C Vulcano, LA Cubillos, BM Korenblat Donato Source Type: research

Patient Preferences for Oral Anticoagulation Therapy in Atrial Fibrillation: A Systematic Literature Review
Conclusion Stroke risk reduction and a moderate increase in the risk of bleeding are the most important attributes for an AF patient when deciding whether they are for or against OAC treatment. If different anticoagulation options have similar clinical characteristics, convenience attributes matter to patients. In this review, AF patients favour attribute levels that describe NOAC treatment.
Source: The Patient - Patient-Centered Outcomes Research - July 25, 2016 Category: Global & Universal Source Type: research

Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina
Abstract Apixaban, a novel oral anticoagulant which has been approved for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation, reduces both ischemic and haemorrhagic stroke and produces fewer bleedings than vitamin K antagonist warfarin. These clinical results lead to a decrease in health care resource utilization and, therefore, have a positive impact on health economics of atrial fibrillation. The cost-effectiveness of apixaban has been assessed in a variety of clinical settings and countries. However, data from emergent markets, as is the case of Argentina, are still scarce. ...
Source: Health Economics Review - June 26, 2015 Category: Global & Universal Source Type: research

Cost-Effectiveness of Edoxaban In Patients With Non-Valvular Atrial Fibrillation In Hong Kong
Atrial fibrillation (AF) is a common arrhythmia associated with debilitating consequences such as stroke, heart failure and venous thromboembolism. In HK, 20-25% of stroke cases are related to AF leading to a significant burden. Warfarin has been the frontline oral anticoagulant for AF but with high bleeding risk and hence monitoring and dose adjustment are required. The non-vitamin-K antagonist oral anticoagulants (NOACs) are alternatives to warfarin for preventing stroke and systemic embolism in non-valvular AF (NVAF) patients.
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: DB Wu, WY Choon, KK Lee Source Type: research

Eating habits in the population of the Aeolian Islands: an observational study.
CONCLUSIONS: Study findings show the eating habits and health status of the Aeolian people in an interesting setting of low incidence of cerebrovascular disease. This nutrition regimen has been proved to be protective against cerebrovascular disease. Nutrition is likely to contribute to the low incidence of stroke in this population. PMID: 30585144 [PubMed - as supplied by publisher]
Source: Public Health Nutrition - December 26, 2018 Category: International Medicine & Public Health Authors: La Spina P, Savica R, Ciacciarelli A, Cotroneo M, Dell'Aera C, Grillo F, Casella C, Fazio MC, Trimarchi G, Musolino RF Tags: Public Health Nutr Source Type: research

Direct oral anticoagulants in treatment of cerebral venous thrombosis: a systematic review protocol
DiscussionCurrent guidelines in the treatment of cerebral vein thrombosis dating back to 2011 from the American Heart Association/American Stroke Association endorse the utility of anticoagulation for the treatment of cerebral vein thrombosis; however, they did not support the use of direct oral anticoagulants. Updated guidelines from the European Stroke Organization, endorsed by the European Academy of Neurology in 2017, also refute utilization of direct oral anticoagulants due to a lack of evidence. There have been nearly 10  years of experience with direct oral anticoagulants in the treatment of venous thrombosis and ...
Source: Systematic Reviews - April 17, 2019 Category: International Medicine & Public Health Source Type: research

PCV57 Persistence to Warfarin Among Patients with Atrial Fibrillation and Comorbid Hypertension, Diabetes and Hyperlipidemia
The objective of this study was to examine the persistence to Warfarin and to evaluate the predictors associated with non-persistence to Warfarin among patients with comorbid AF, diabetes, hypertension, and hyperlipidemia.
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: A. Mohan, Z. Majd, R. Paranjpe, A. Vadhariya, O. Serna, S.M. Abughosh Source Type: research

The Uptake of Non-Vitamin K Oral Anticoagulants in Ireland: Balancing Cost-Effectiveness Analysis and Budget Impact
For many years vitamin K antagonists (usually warfarin) were the only oral anticoagulants available to reduce stroke risk in Atrial fibrillation (AF). The non-vitamin K oral anticoagulants (NOACs) were first licensed in Ireland for stroke prevention in non-valvular AF with the approval of dabigatran etexilate in 2011. Rivaroxaban followed later that year, apixaban in 2013 and edoxaban in 2015. The National Centre for Pharmacoeconomics (NCPE) reviewed all the NOACs for cost-effectiveness prior to reimbursement approval in Ireland.
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: M Barry, S Clarke, N Geraghty Source Type: research